Arvin Capital Management LP Increases Stake in Danaher Co. (NYSE:DHR)

Arvin Capital Management LP grew its position in shares of Danaher Co. (NYSE:DHR - Free Report) by 34.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 42,001 shares of the conglomerate's stock after acquiring an additional 10,831 shares during the quarter. Danaher accounts for approximately 2.7% of Arvin Capital Management LP's portfolio, making the stock its 15th largest holding. Arvin Capital Management LP's holdings in Danaher were worth $9,641,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in DHR. Heck Capital Advisors LLC purchased a new stake in Danaher in the 4th quarter valued at about $27,000. Decker Retirement Planning Inc. bought a new stake in Danaher during the fourth quarter worth $31,000. Golden State Wealth Management LLC purchased a new position in Danaher in the fourth quarter worth $31,000. Strategic Financial Concepts LLC bought a new position in Danaher in the 4th quarter valued at $31,000. Finally, Pineridge Advisors LLC increased its position in shares of Danaher by 63.3% during the 4th quarter. Pineridge Advisors LLC now owns 147 shares of the conglomerate's stock valued at $34,000 after purchasing an additional 57 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company's stock.

Danaher Price Performance

Shares of DHR traded up $0.87 during mid-day trading on Friday, reaching $197.37. 2,608,666 shares of the stock traded hands, compared to its average volume of 3,354,979. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. Danaher Co. has a 1 year low of $171.00 and a 1 year high of $281.70. The company has a market cap of $141.06 billion, a price-to-earnings ratio of 37.38, a price-to-earnings-growth ratio of 2.66 and a beta of 0.86. The firm has a fifty day moving average price of $200.87 and a 200 day moving average price of $223.98.

Danaher (NYSE:DHR - Get Free Report) last announced its earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, topping analysts' consensus estimates of $1.62 by $0.26. The business had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.58 billion. Danaher had a return on equity of 10.82% and a net margin of 16.33%. As a group, equities research analysts predict that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, April 25th. Stockholders of record on Friday, March 28th were issued a $0.32 dividend. This is a positive change from Danaher's previous quarterly dividend of $0.27. The ex-dividend date of this dividend was Friday, March 28th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.65%. Danaher's dividend payout ratio is presently 24.85%.

Analyst Ratings Changes

A number of equities analysts recently weighed in on DHR shares. Robert W. Baird cut their price target on shares of Danaher from $231.00 to $225.00 and set an "outperform" rating on the stock in a report on Wednesday. JPMorgan Chase & Co. reduced their target price on shares of Danaher from $280.00 to $260.00 and set an "overweight" rating for the company in a research report on Tuesday, April 22nd. UBS Group lowered their price target on shares of Danaher from $275.00 to $240.00 and set a "buy" rating on the stock in a report on Wednesday. Guggenheim reissued a "buy" rating and set a $250.00 price objective on shares of Danaher in a report on Wednesday. Finally, Barclays boosted their target price on Danaher from $205.00 to $215.00 and gave the company an "overweight" rating in a research note on Tuesday, April 22nd. Five research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $264.40.

Insider Activity

In related news, SVP Brian W. Ellis sold 5,700 shares of the stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the transaction, the senior vice president now owns 20,230 shares of the company's stock, valued at $4,534,149.90. This represents a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 11.10% of the company's stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.